The present invention relates to an optical stimulation arrangement including a light-emitting element, and methods and devices for driving the light-emitting element.
Neuroprosthetic intervention involves the recording of electrical activity from nerve cells and/or the inducement of new electrical activity in those cells. In so doing therapeutic benefit can be obtained. The very first commercialised neuroprosthesis was the heart pacemaker which was originally developed in the 1950's. This intervention has benefitted many by properly regulating the beating of the human heart. In the 1970's cochlear prosthetics were developed for the deaf. Such devices would pass auditory information from a microphone and pass it the brain by stimulating the cochlear nerve. Since then there have been developments in many areas including pacemakers for deep brain disorders such as Parkinson's disease, functional nerve stimulators to return motor function in the physically disabled, and visual prosthesis for the blind1. 1 Barrett John, Berlinguer-Palmini Rolando, Degenaar Patrick. Optogenetic approaches to retinal prosthesis. Visual Neuroscience 2014, 31(4-5), 345-354
The human nervous system consists of neuron cells which transmit information in an electrical manner within the cell and chemical manner between cells. The electrical model of the nerve cell was defined by Hodgkin and Huxley in 1956 {A. L Hodgkin, 1952 #38}2. Electric activity is modulated by ionic flow in and out of cells, which is determined via chemically or electrically activated channels on the cell membrane. As such, the traditional method for recording and stimulating information flow in neurons has been with electrical means [1]. In particular, for the latter case, electrodes would pass charge (electrical current) into the 2 A. L. Hodgkin and A. F. Huxeley A quantitative description of membrane current and its application to conduction and excitation in nerve. J. Physiol (1950) 117, 500-544 medium close to the cell and create a change in voltage across the cell membrane. This stimulus would activate electrically gated ion channels in the nerve cell membrane and would be followed by a reversal phase in the electrode to balance charge and prevent electrolysis.
In 2003, the ectopic expression of light-sensitive ion channels was first demonstrated [2]. This channel, known as channelrhodopsin-2 (ChR2) allows nerve cells to be stimulated with light of specific wavelengths. It has given rise to a field known as optogenetics—the genetic manipulation of cells to become photosensitive. In addition to ChR2, other photosensitive surface proteins are under investigation. Light sensitive ion pumps such as halorhodopsin {Zhao, 2015 #39}3 and light-activated protein amplifiers such as melanopsin [4, 5], and modified optically sensitive channels can provide a range of capabilities. These include both stimulus and inhibition from different wavelengths of light. These new tools have been revolutionary in the fields of electrophysiology and prosthetics [3-5]. As the sensitizing proteins can be genetically engineered into specific kinds of neurons, this technique can be fully used to explore complex brain circuits and neurological and psychiatric illnesses such as blindness, spinal cord injuries, Parkinson's disease and epilepsy [6-8]. Equally, this technique can potentially replace the use of electrical stimulus in medical neuroprosthetics, and the emerging field of bioelectronic medicine (also known as electroceuticals). 3 M. Zhao et al., “Optogenetic tools for modulating and probing the epileptic network,” Epilepsy Research, vol. 116, pp. 15-26, Oct, 2015
The key advantages of optogenetics over electric stimulus are multifold:
The key requirement in optogenetics is to deliver intense light (typically up to 1 mW/mm2 in pulses of around 10 ms) locally to the nerve cells [2, 3]. The wavelength sensitivity peaks vary between different opsin proteins. The light sensitive core of these proteins—retinal, is the same as for the rhodopsin's used in mammalian vision. As such, their chemistries can be tuned across the visible range of the electromagnetic spectrum. The light requirement varies with both the opsin type and the efficiency of genetic expression on the cell membrane. At the time of writing the most commonly used wavelength is 470 nm (blue) for channelrhodopsin. However, shorter wavelengths, in particular, scatter strongly in tissue, requiring either extremely intense stimulus from an internal source or a local stimulus close to the nerve cell. The light requirement is a function of the irradiance and illumination time. Opsins have light and dark adapted states. So short radiance illumination is preferable4, though the efficiency of most light emitters decreases with intensity, so a trade-off is required between the two. 4 Grossman N, Nikolic K, Toumazou C, Degenaar P. Modeling Study of the Light Stimulation of a Neuron Cell With Channelrhodopsin-2 Mutants. IEEE Transactions on Biomedical Engineering 2011, 58(6), 1742-1751
In addition to optogenetic stimulus or neural activity, there is also increasing interest in optical probing of neurological function. Genetically encoding of reporter dyes such as gCAMP3 [6] can be used to measure cell activity directly. Furthermore, such dyes can be linked to calcium function and have thus potential in determining other functions in both neurological and non-neurological cells. Furthermore, in the non-optogenetic field, optical probing of cellular autofluorescence through fluorescence lifetime measurements and related techniques can report back useful information. Such techniques involve illuminating tissue in a similar fashion as per optogenetics and then recording spectrally or temporally shifted information using light recording techniques such as photodiodes. As the stimulus is typically on the bluer end of the spectrum [7], the same principles of light scattering apply, requiring the same principles of light delivery.
Given scattering effects in tissue, light may be delivered locally either through an optic guiding mechanism from afar [8] or via local generation on a penetrating probe [9]. The former is potentially convenient when very few individual stimulus points are required. Optical multiplexing is very challenging to incorporate into micro-sized penetrating probes. Probes have therefore been developed with multiple light guides [8] and multiple connection points. However, in this case, there is a complexity issue with the coupling of multiple individual light emitters with low losses, which is currently unsolved. The alternative approach is to develop probes which generate light locally in the tissue. Such devices are limited in intensity by thermal heating limits in tissue, but can still provide sufficient radiance to achieve suitable stimulus [10].
Light generation, either locally on the probe or by light guided methods can be achieved primarily by light emitting diodes [9, 11], lasers5, or by light emitting diodes with laser-like properties6 In all cases, the energy used to generate light will originate in electrical form, whether it comes from a battery, is scavenged in some form from the body, or transmitted percutaneously. As such, the typical configuration consists of an anode and cathode contact between the electrical circuit and the light emitter. It is additionally conceivable to have light emitting transistor structures7. 5 Hamaguchi, T., Fuutagawa, N., Izumi, S., Murayama, M., & Narui, H. (2016). Milliwatt-class GaN-based blue vertical-cavity surface-emitting lasers fabricated by epitaxial lateral overgrowth. Physica Status Solidi a-Applications and Materials Science, 213(5), 1170-1176. doi: 10.1002/pssa.2015327596 Hu, X. L., Liu, W. J., Weng, G. E., Zhang, J. Y., Lv, X. Q., Liang, M. M., . . . Zhang, B. P. (2012). Fabrication and Characterization of High-Quality Factor GaN-Based Resonant-Cavity Blue Light-Emitting Diodes. Ieee Photonics Technology Letters, 24 (17), 1472-1474. doi: 10.1109/Ipt.2012.22061107 Raffaella Capelli, Stefano Toffanin, Gianluca Generali, Hakan Usta, Antonio Facchetti & Michele Muccini “Organic light-emitting transistors with an efficiency that outperforms the equivalent light-emitting diodes” Nature Materials 9, 496-503 (2010)
The emitter, whether in laser, laser-like or light emitting diode form, is typically constructed from an emissive semiconductor layer sandwiched between conductive structures which respectively provide the electrons (cathode) and holes (anode). The semiconductor layer may be constructed from organic substrates8, inorganic crystal9 or quantum dots10. 8 Raffaella Capelli, Stefano Toffanin, Gianluca Generali, Hakan Usta, Antonio Facchetti & Michele Muccini “Organic light-emitting transistors with an efficiency that outperforms the equivalent light-emitting diodes” Nature Materials 9, 496-503 (2010)
Liu, J., Zhang, H. T., Dong, H. L., Meng, L. Q., Jiang, L. F., Jiang, L., . Heeger, A. J. (2015). High mobility emissive organic semiconductor. Nature Communications, 6, 8. doi: 10.1038/ncomms10032 9 Maaskant, P. P., et al., High-Speed Substrate-Emitting Micro-Light-Emitting Diodes for Applications Requiring High Radiance. Applied Physics Express, 2013. 6 (2).10 P. Anikeeva; J. Halpert; M. Bawendi; V. Bulovic (2009). “Quantum dot light-emitting deices with electroluminescence tunable over the entire visible spectrum”. Nano Letters. 9 (7): 2532-2536Seth Coe; Wing-Keung Woo; Moungi Bawendi; Vladimir Bulovic (2002). “Electroluminescence from single monolayers of nanocrystals in molecular organic devices”. Nature. 420 (6917): 800-803.
Optogenetic illumination requires ultra-bright emission, which may be beyond the best organic light emitting diode (OLED) structures currently be produced11. The same may be true for quantum dots. Additionally, the operational lifetime of OLEDs decreases inversely with the operational current density. As the drive current density is directly proportional to the LED area and emitter radiance, their suitability for optogenetics is currently limited. However, as the molecular biology improves and the light requirement is reduced, they may prove to be useful tools in the future as their emission wavelength peaks are broadly tuneable through chemistry from violet through to the near infra-red12. 11 Liu, J., Zhang, H. T., Dong, H. L., Meng, L. Q., Jiang, L. F., Jiang, L., . . . Heeger, A. J. (2015). High mobility emissive organic semiconductor. Nature Communications, 6, 8. doi: 10.1038/ncomms1003212 Soultati, A., Papadimitropoulos, G., Davazoglou, D., Argitis, P., Alexandropoulos, D., Politi, C. T., . . . Ieee. (2015). Near-IR Organic Light Emitting Diodes Based on Porphyrin Compounds 2015 17th International Conference on Transparent Optical Networks
The same principle holds true for quantum dot technologies whose emission spectra are tuneable through the size of the quantum dot. However, quantum dots typically contain cadmium or lead which is toxic if leached out into the body through degradation. Acute and short-term studies of encapsulated quantum dots in animals has been performed without ill-effect. However, long-term studies indicate significant toxicity13. 13 Cao, Y. H., Wang, D., Li, Q. Z., Deng, H. L., Shen, J., Zheng, G. Y., & Sun, M. (2016). Rat Testis Damage Caused by Lead Sulfide Nanoparticles After Oral Exposure. Journal of Nanoscience and Nanotechnology, 16(3), 2378-2383. doi: 10.1166/jnn.2016.10938
Inorganic light emitting diode materials such as Gallium Nitride (GaN: violet to green emission) and Aluminium Gallium Indium Phosphide (AlGaInP) allow for much higher current densities. In particular, GaN can be tuned within the 450 nm-510 nm range which matches the most common opsin absorption peak of 470 nm. They can be fabricated into microscale dimensions and are constructed with multiple quantum well layers for efficiency. Crucially for implantable devices, their operational lifetimes are long, even for relatively high current densities, and there is no current evidence of cytotoxicity from degradation products. Thus, they are a primary candidate for high-radiance optogenetic stimulation are gallium nitride based LEDs [14, 15].
For sensing applications, including optogenetic sensing, lower light intensities may be acceptable, allowing organic and quantum dot emissive technologies. Furthermore, in some cases, the primary wavelength of interest may be in the infra-red. In such cases, Aluminium Gallium Arsenide, which is used extensively in the telecoms sector can be applied.
In the case of local light generation on the probe, the optical emitter will be near the tissue interface, and therefore there is the possibility of electrochemical degradation. In the case of light guided probes, if the optical emitter is potentially further away from the tissue and under greater encapsulation. However, it may still be susceptible to degradation. Therefore, this application is directed towards ways in which electrochemical degradation of anode and cathode contacts in implantable optical emitters may be prevented or reduced.
Before turning to the invention in detail, it is useful to understand the mechanisms by which degradation of anode and cathode contacts may occur.
Electrochemical degradation is a well-known and understood phenomenon. If a metal is placed in a saline solution, electric fields between the metal and saline will induce ion transfer. This transfer will result in the degradation of the metal in the interface with the solution. Wang, Q., Zhou, Y. F., Song, B., Zhong, Y. L., Wu, S. C., Cui, R. R., . . . He, Y. (2016). Linking Subcellular Disturbance to Physiological Behavior and Toxicity Induced by Quantum Dots in Caenorhabditis elegans. Small, 12(23), 3143-3154. doi: 10.1002/smll.201600766
In the case of implantable electronic devices, electrodes typically have circuits and capacitive structures which try ensure that any electrical interaction with the body has no net charge i.e. direct current delivery. Rather, electrode stimulus is presented in an alternating current (AC) fashion with any positive charge pulse matched by a negative charge pulse. The integral function of the two pulses needs to be zero.
However, electrode structures are surface facing and thus in direct contact with the tissue fluid. Other structures will have passivation layers (e.g. silicon dioxide or silicon nitride) and are typically encapsulated with a polymer such as silicone or parylene. In other configurations, there may only be a ceramic passivation layer or a polymer coating. Their degradation mechanism is less obvious as there should be no electrochemical interface. Most polymers can allow for limited aqueous transmission. Therefore, any cavity caused by defects in the interface between the passivation material and the active layers will attract and be filled with water and/or saline. Such defects may be inherent in particular manufacturing processes. Alternatively, they may be created over time due to delamination between layers or through aging-related stresses or chemical changes in the materials.
The creation of saline filled cavities can start electrochemical degradation in neighbouring structures if there are electric fields. Typically, electrical lines controlling electrodes, and surface photonic structures will be placed in a dielectric stack near the surface as per
Furthermore, there is a process whereby electrochemical exchange with a fluid filled cavity can cause expansion of the cavity and thus further delamination. Such processes can expand a failure point from a very localized region to the whole implant. The degradation process is very nonlinear, so difficult to determine and predict. However, in more generalised terms, the process will be hastened by the strength of net electric fields, and the temporal duration of the field. Implantable structures need to be small. Thus, the distance between electrically active structures is small, which in turn increases electric field strength (=voltage/distance). Optogenetic stimulation is typically in the 1-100 millisecond range to provide sufficient activation. Though short, significant degradation processes may occur at this time. These effects are clearly undesirable, particularly in implants which are placed in the brain and are difficult to explant and replace.
Methods are therefore required to reduce such degradation mechanisms. These include better manufacturing techniques to prevent voids, choice of materials, and design of electrical lines with sufficient spacing to reduce electric field strengths.
In contrast to electrodes, light emitting structures have a strongly rectified current-voltage operation. Thus it is not feasible to balance charge over time. However, such currents are not actually in contact with the solution. So the mechanism of degradation is quite different to electrode driving. Rather it is the electric fields which may cause ionic flows between electrodes and any fluid filled cavities. As such, the principle is to balance electric fields on the cathode and anode with respect to time.
Numerous illumination systems exist in industry. Increasingly organic light emitting diodes (OLEDs) are being utilised in displays for both emplaced and mobile systems. Although OLEDs have the potential for beautiful quality displays, it has been notoriously difficult to ensure operation in years rather than months. As such, much effort has been placed on exploring methods to ensure their long-term lifetime.
For consideration with regards this invention, researchers in this field have considered electronic biasing techniques to minimize long term degradation. Eisenbrand et al. [12] have considered separating sub-frame pulse width intensities to reduce current voltage stresses. But their proposed degradation mechanism is related to current density and [current×time] rather than through electrochemical mechanisms. Other researchers in the OLED field have considered biphasic operation.
Lin et al. [13] considered the problem of long-term threshold voltage Vth change in the organic diodes. Simply increasing the supply over time steadily increases the rate of degradation and thus the operational lifetime of the device. They thus considered an alternative positive/negative biasing scheme to reduce the effect of Vth change without hastening the electric field induced degradation.
Such reported biphasic operation in the driving of OLEDs is operating on a fundamentally different principle to the electrochemical mechanism proposed in this invention. Furthermore, their implementation is a three transistor circuit within a matrix scheme with a global positive/negative bias. In our case, not only is the fundamental physics of the degradation effect different, but we are considering both the effects of differential electric fields between cathode and anode and common fields between cathode/anode and the tissue. As such, the circuitry we propose is very different.
Previously, optical systems for retinal prosthesis have been demonstrated [11, 16], but in this configuration, the illumination system is external to the body. As such, the control transistor is simply implemented to provide maximum power per pixel and modulated in time. Alternatives could be to modulate with current, but it is not necessary to consider voltage balancing. Others have also considered high power light emitting diode arrays for illumination purposes [14, 17]. However, in these cases, although the circuitry is not presented, there is also no requirement for voltage balancing during operation, and such operation is not mentioned in the text.
Some groups, have considered implantable probes incorporating LEDs [9, 10, 18]. Some such as McAlinden et al. [9] have created probes directly from the Gallium Nitride. Others such as Cao et al., and Clements et al. [19, 20] have developed silicon-based probes with embedded Gallium Nitride LEDs. However, most of these groups have used discrete current drivers and microcontrollers to drive the current. Past work by the Degenaar team has described microelectronic drive circuits in the form of a H-tree circuit which can provide current steering approaches which can use the reverse current for diagnostic purposes [18]. However, electric field balancing [voltage×time] for long-term degradation prevention has not previously been demonstrated.
In order to prolong the lifespan of the light-emitting element by prevention of degradation caused as a result of net electric fields, the present invention provides at its most general, an optical stimulation arrangement in which a light-emitting device is driven in a manner which balances out the voltage-time profiles in a biphasic manner, in order to invert any charge which has built up in its surrounding environment. In other words, structures with potential exposure to aqueous fluid need to obey two rules:
As microelectronic structures can have placements much closer to each other than with the common tissue, rule 1 is in many cases most significant. Additionally, as microphotonic (or similar sensor/actuator) structures are bonded onto the surface of microfabricated probes, the most significant effect will be on the anode and cathode contact of the microphotonic device. Where there is a plurality of contacts, for example in a 3 contact light emitting transistor, the principle can simply be extended for all contacts. Furthermore, the control lines which connect to these contacts are also susceptible to degradation and should where possible operate under the same principles.
These principles hold true for other electrically active devices that are embedded on implantable probes. These may include Micro Electro Mechanical Systems (MEMS), microbolometer or solid state thermal sensors, piezo actuators, memristors, antennae and rectennae. These have different operational voltage properties, but the mechanism by which they may degrade through electric field induced electrochemical degradation is the same. For brevity, we describe the specific microphotonic case, but the inventive circuitry holds true for all.
Accordingly, a first aspect of the present invention provides an optical stimulation arrangement including:
Optional features of the invention will now be set out. These are applicable singly or in any combination with any aspect of the invention.
Preferred embodiments of this invention are directed towards optical stimulation of tissue, and preferably neural tissue such as brain tissue or retinal tissue. There is also a growing body of work in the field of bioelectronics medicine (also known as electroceuticals) which may require such devices to be placed in non-neural tissue. In these cases, the surrounding environment is the tissue itself and the associated ground voltage is referred to as “the tissue ground” or “gndtissue”. Stimulation of neural tissue has important applications for optogenetic techniques, as described earlier in this application.
In preferred embodiments of the present invention, the light-emitting element is a semiconductor light-emitting element such as a light-emitting diode (LED), a laser, or a light emitting diode with partial laser-like qualities. The operational physics of these devices is different, but they have similar current-voltage characteristics, which is important for the present invention. The most important consideration is the rectification properties which will determine the stimulation and reversal driving profiles.
The light emitting element may be constructed from organic semiconductor material such as 2,6-diphenylanthracene (DPA), inorganic crystalline materials such as gallium nitride (GaN), or quantum dots such as CdSe/ZnSe. Generally, for Implantable devices there is a requirement for high radiance stable devices with non-toxic byproducts. GaN therefore can provide the primary wavelength of 470 nm for some opsins, and AlGaInP for the 590 nm peak. Alternative materials can be used for other requirements including sensing requirements.
The spectral range required for stimulating different opsin forms ranges from 450 nm-650 nm. For sensing applications, this range may extend to the infra-red.
The anode and cathode of the light-emitting device may be connected directly to a power supply, which may be included in the optical stimulation arrangement. Alternatively, the optical stimulation arrangement may be connectable to an external power supply, such as a battery. Specifically, the biphasic driving of the light-emitting device is achieved by controlling the voltage inputs at the anode and the cathode. The controller may be configured to drive the light-emitting device with a stimulation phase and a reversal phase, each having an associated voltage-time profile, and preferably wherein the voltage-time profile associated with the reversal phase is selected to balance out the voltage-time profile associated with the stimulation phase. In this way, net electrochemical oxidation/reduction (or addition or subtraction of material) from the anode/cathode with respect to an adjacent aqueous layers will be reduced. The lifetime of the anode/cathode and/or the control lines is thus prolonged, thus prolonging the life of the light-emitting device. As the name suggests, the light emitting element is preferably in an ON state during the stimulation phase. Ideal diodes have zero current under reverse bias. However, in practice, there will be a leakage current defined by the rectification properties of the diode. Typically, this is in the nano-amps range and is non-radiative. So, in preferred embodiments, the light-emitting element is in an OFF state during the discharge phase.
The voltage-time profiles associated with the stimulation and reversal phases may be selected to balance out by selecting the reversal phase so that the integral of its voltage-time profile is equal or substantially equal to the negative of the integral of the voltage-time profile associated with the stimulation phase. In this way the charge built up as a result of the electric fields associated with the applied voltages sums to zero, or substantially zero, reducing the extent of any degradation.
Some electrochemical degradation is irreversible, but such processes also have time constants. So it is advantageous to modify the stimulation and reversal times to be short. In the preferred embodiment ON illumination times are in the range of 1-100 ms (but may be 1 microsecond to 100 ms). However, the total illumination time can be interleaved with multiple stimulation and reversal phases. As such, the integral function of the stimulation remains the same for a single longer pulses. However, by utilising higher speed interleaving, whereby the pulse width of the stimulation phase is 1-1000 microsecond, a further reduction in degradation can be achieved. In such cases there may need to be an increase in the total integral illumination to compensate for opto-neural adaptation effects beyond 10 ms.
In preferred embodiments, the controller may be configured to drive the light-emitting device in a third state, referred to herein as a neutral phase. In this state, the voltage across the anode and the cathode are the same as the ground level of the surrounding environment. In preferred embodiments, during the neutral phase, the voltage is clamped to the tissue ground level. It is envisaged that the controller causes the light-emitting device to be in the neutral phase between periods when optical stimulation of the environment is required. In this state, since the anode and the cathode are both fixed at the ground voltage, there is no differential voltage difference between the two, nor is there a voltage between them and the surrounding environment, and accordingly, no electric fields arise, and degradation is minimized.
In order to switch between the two or three phases as described above, the controller preferably includes control circuitry configured to switch between the phases. In particular, the control circuitry preferably includes a switching arrangement configured to switch between all of the phases. For example, in embodiments where there are only two phases, it is preferable that the control circuitry is switchable between two configurations (one in which the stimulation phase is selected, and one in which the reversal phase is selected). The same applies for the preferred embodiments which further cater for a neutral phase (i.e. a third configuration is available). The control circuitry preferably includes at least one switch in order to effect switching between the various phases. Furthermore, the control circuitry preferably also includes a current source. In preferred embodiments, one or both of the at least one switch and the current source may be implemented using one or more transistors. More details of this implementation are set out in the “Detailed Description” section. Transistors may also be used to ensure clamping to the ground level (e.g. tissue ground) in the neutral phase. Furthermore, in order to ascertain the ground voltage to which the voltage across the anode/cathode must be matched, the control circuitry (or another part of the controller) preferably includes means for measuring the associated ground voltage. This means may also be implemented in the form of a transistor, as is explained in detail later on in the application.
As has been discussed previously, a preferred application for optical stimulation arrangements according to the present invention is in the stimulation of body tissues, particularly neural tissue. Accordingly, the light-emitting device, which may be in the form of an optrode, or a plurality of optrodes. The optrode(s) are preferably mounted on a mounting plate, the arrangement of optrode(s) and mounting plate forming an implant which is implantable into the tissue of a user. The tissue is preferably neural tissue. In such configurations, the controller is preferably separate from the light emitting device, but connected to it, e.g. via a connective lead. The controller may be contained in a central control unit connected to the light-emitting device via connective leads or via a wireless connection. The central control unit may also include the above-mentioned power supply, e.g. a battery pack. Alternatively, the central control unit may be configured to receive a battery. In use, the central control unit may also be implanted into the user, though not necessarily in the same place as the light-emitting element. For example, as is discussed later, the central control unit may be implanted in the chest.
In order to communicate with devices external to the optical stimulation arrangement of the present invention, the controller may include means for wirelessly communicating with external electronic devices, e.g. for control purposes. This communication may, for example, be in the form of Bluetooth or VVi-Fi communication. The wireless communication preferably falls within accepted ISM or Medradio bands.
A second aspect of the present invention provides a controller configured to drive a light-emitting device in a biphasic manner, the light-emitting device being implantable in an environment with an associated ground voltage. All of the optional features presented above may also be combined with embodiments of the second aspect of the invention, where compatible.
A third aspect of the present invention provides a method for driving a light-emitting device in a biphasic manner. As with the second aspect of the invention, the optional features which are set out with respect to the first aspect apply equally to the third aspect, where applicable.
Further optional features of the invention are set out below, described in detail with respect to the attached drawings. These optional features, again, are compatible with all aspects of the invention.
Embodiments of the invention will now be described by way of example with reference to the accompanying drawings, summarized briefly below.
In addition to the description of the embodiments set out below, further detailed description of the embodiments is set out in Annex A, titled “Biphasic Micro-LED Driver for Optogenetics”.
There are some different configurations for the interface unit, which are described in
Multiple independent probes incorporating multiple independent illumination elements require internal microelectronics for control and multiplexing. Such electronics are described in
The typical operation of a light emitter from the perspective of anode voltage is given in
The traditional operation, described above, results in both net electrode fields common to the cathode/anode and the tissue, and differential between cathode and anode. Resultant net electric fields can cause electrochemical degradation in the long term should defects create cavities which then fill with saline. As such, to reduce these effects, both the differential fields between anode and cathode and common field with the tissue need to be reduced, preferably to zero.
The principle of operation is analogous to electrode charge balancing except that in this case, it is the electric fields with needs to be balanced. Thus the integral of the voltage with time should be balanced by the integral of the negative voltage over a given time.
The total optical stimulus will be an integral function of the irradiance on the cell with respect to time. There is a limit to the maximum light output of LEDs, so typical stimulus times or in the period of 1-100 ms. However, longer periods of net electric fields increase the possibility of non-reversible electrochemical activity at the anode/cathode-fluid interface. As such, the stimulation/reversal cycle time can be shortened and repeated such that the total stimulation time is the same as for a single, longer stimulation/reversal cycle. This concept is presented in
So far, the simple case of pulse modulation has been explained. However, there is a further issue with regards stimulus artefact.
Although the coupling between the LED and the tissue electrolyte is capacitive, it has been demonstrated in the literature that such connections can act be inductive14. The effect can thus be seen in
The basic property of inductive AC operation is that that the induced charge varies with the derivative of the electrical field change. As such, a high frequency (step function) change will cause the maximum possible effect, whereas a low frequency (sloped function) will have minimal effect. This is demonstrated in
As such, any system can have a function of artefact response versus slope angle. Which can be seen in
An exemplar implementation and pseudo code can be seen in
Pseudo code for achieving this functionality in the digital control unit in
The arrangement of processing for such functionality is for a local finite-state-machine in the optrode and an external controller to drive it. An alternative embodiment may be that all digital functionality remains outside the optrode device with analog lines directly controlling passive components. Or another alternative embodiment may be that the digital drive protocol would be fully incorporated either on the optrode digital microelectronics (active probe) or as a bolted-on unit in tandem with the optrode or an optrode array.
The above described control may be achieved by the central control unit presented in
In practice the effective clock cycle, i.e. when considering it may take more than one clock cycle to implement an action, will determine the cycle time. (c) Describes this effect. Typically the voltage between stimulation and reverse is different. But the minimum cycle ratio is determined by the quantization error from the effective clock. In this case, cycles can be implemented which do not exactly match per cycle, but match over a number of cycles.
The power supply to the optrodes is described in
A central control unit, typically placed in the chest converts a direct current supply from a battery into an alternating supply which oscillates around tissue ground. Such data/power transmission is common in implantable units as it ensures no net charge dissipation into the tissue in the case of cable rupture. A power conversion system in the optrodes then reproduces a direct current with the tissue ground potential at the centre of the Vdd supply and Vss voltages.
To achieve biphasic operation around the tissue ground point, we utilise a conceptual operation is described in
A current source determines the level of current flow and thus light output in the reversal phase. Switches then allow for the three phases: stimulation, neutral, and reversal. In the reversal phase (b), current flows in the forward direction through the diode allowing light emission. In the reversal phase (c), current flows in the reverse direction. The current flow, in this case, is very small and related to the leakage properties of the diode. For most emitter configurations, no light is emitted in this phase. In the off state, the voltage across the anode and cathode are clamped to ground. In practice, these switches and the current source are implemented as transistors. The applied voltages across the anode and cathode will then be determined by the configuration of the implemented transistors and the current-voltage profile of the emitter.
A circuit implementation of this operation is described in
Transistors M3 and M4 act as switches to mediate current flow in the stimulation and reversal phases. During operation both transistors will generally be in the triode operational region as much of the Vdd-Vss voltage will drop across the diode constraining the source-drain voltage of the transistors. As such, they act more precisely like voltage controlled variable resistors than ideal current sources.
M5-M8 allow clamping the anode and cathode to tissue ground. These can be included if the resting potential of the anode and cathode without such structures deviates from tissue ground. This is typically the case if M1-M4 are not the same size. The reverse current through M2 will differ from the stimulation current through M1. Thus, the W/L ratios of these transistors are different. Furthermore, the midpoint of Vdd and Vss as defined in
If the deviation from tissue ground is small, M6 and M7 can be negated. Additionally, if a triple well or SOI CMOS process can be used with an isolated n-well, then the body of M5 and M8 should be connected to tissue ground to prevent a body effect. Switches S1 to S10 represent digital switches which can be implemented as transistors. For some ‘AMP’ implementations, it may be difficult to achieve the maximum values of Vdd and Vss to correspond with the DAC values 0 and 255. Thus, S1 and S4, can be used to clamp to Vdd, and S3 and S6 to clamp to Vss.
The stimulation and reverse phases can be achievable by switching the related transistors on or off. For example, the stimulation phase requires M2 and M3 (and M5-M8) transistors to be off and M1 and M4 transistors to be ON. The cycle time can be achieved through rapid ON-OFF switching with the integral ON time providing pulse width modulation. Furthermore, current control will be done using DAC and through TCA. In reverse mode, M1 and M4 are off, and M2 and M3 are controlled by control logic for PWM and DAC for current control. The full table of operation is provided in
Light emission in the configuration presented in
To minimize degradation effects, the [voltage×time] of the anode in the stimulation phase must equal the −[voltage×time] in the reversal phase. The same must be true of the cathode. To achieve such balancing operation, two different strategies may be used:
(2) Changing the time period of the reversal phase to match the integral function of the voltage in the stimulation phase with time. Although the stimulation/reversal cycle can be operated at sub-millisecond, the practical time will be a function of the required matching accuracy and the minimum switch time.
The local state switching settings are defined in a table in
While the invention has been described in conjunction with the exemplary embodiments described above, many equivalent modifications and variations will be apparent to those skilled in the art when given this disclosure. Accordingly, the exemplary embodiments of the invention set forth above are considered to be illustrative and not limiting. Various changes to the described embodiments may be made without departing from the spirit and scope of the invention.
All references referred to above and below are hereby incorporated by reference.
Number | Date | Country | Kind |
---|---|---|---|
1616725.6 | Sep 2016 | GB | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP2017/074866 | 9/29/2017 | WO | 00 |